NPD Measurements in PSC Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00476814|
Recruitment Status : Unknown
Verified October 2007 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : May 22, 2007
Last Update Posted : October 31, 2007
|Condition or disease|
|Primary Sclerosing Cholangitis|
Cystic Fibrosis (CF) is a progressive autosomal recessive disorder caused by defects in the cystic fibrosis transmembrane conductance regulator gene (CFTR). CFTR mutations cause loss or impairment of CFTR-mediated ion transport across epithelial cell membranes. CF affects many organs including the respiratory tract, pancreas, intestine, liver and the male reproductive tract. Liver disease occurs less frequently than pulmonary disease. CFTR is expressed in the bile duct epithelial cells and is responsible for the hydration of biliary secretions.
CF was until recently, thought to be a multi-organ disease. However, there are now recognized non-classical presentations of CF involving a few organs only and now there is well established data on single -organ involvement including Congenital Absence of the Vas Deferens and recurrent pancreatitis.
CF and PSC have several features in common. They both affect intrahepatic bile ducts by inspisated biliary secretions, chronic inflammation and fibrosis. Is PSC the "single-organ presentation" of CF? Patients with PSC will undergo testing of the CF protein channel by nasal potential testing. This test is performed by insering a thin plastic tube 2 to 3 cms into the nostril and chloride transport can be measured. This test may shows that the patient has an abnormality in the CF protein channel.
|Study Type :||Observational|
|Official Title:||Cystic Fibrosis Transmembrane Conductance Regulator Function as Measured by Nasal Potential Difference Measurements in Patients With Primary Sclerosing Cholangitis|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00476814
|Contact: Michael Wilschanski, Dr.||email@example.com|
|Hadassah Medical Organization||Not yet recruiting|
|Jerusalem, Israel, 91240|
|Contact: Michael Wilschanski, Dr 972-2-5844922 firstname.lastname@example.org|
|Principal Investigator: Michael Wilschanski, Dr|
|Principal Investigator:||Michael Wilschanski, Dr||Hadassah Medical Organization|